Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)

Circulating protein markers were assessed in patients with colorectal cancer (CRC) treated with cetuximab in CALGB 80203 to identify prognostic and predictive biomarkers. Patients with locally advanced or metastatic CRC received FOLFOX or FOLFIRI chemotherapy (chemo) or chemo in combination with cet...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatch, Ace J., Sibley, Alexander B., Starr, Mark D., Brady, J. Chris, Jiang, Chen, Jia, Jingquan, Bowers, Daniel L., Pang, Herbert, Owzar, Kouros, Niedzwiecki, Donna, Innocenti, Federico, Venook, Alan P., Hurwitz, Herbert I., Nixon, Andrew B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055181/
https://www.ncbi.nlm.nih.gov/pubmed/27465221
http://dx.doi.org/10.1002/cam4.806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055181/
https://www.ncbi.nlm.nih.gov/pubmed/27465221
http://dx.doi.org/10.1002/cam4.806

Ejemplares similares